OBX — Obsidian Therapeutics Share News
0.000.00%
Last trade - 00:00- $861.11m
- $861.11m
NASDAQ RESUMED AT 07:30 AM
Brief: Galera Announces Primary Endpoint Met Statistical Significance In Corrected Topline Data Of Avasopasem Phase 3 Trial
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Galera Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Galera Reports Third Quarter 2021 Financial Results And Recent Corporate Updates
Galera shares plummet 69% after drug fails in late-stage trial
NASDAQ RESUMED AT 10:50 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:45 AM
NASDAQ RESUMED AT 07:30 AM
Brief: Galera Therapeutics Inc Announces Results Of Phase 3 Roman Trial Of Avasopasem For Radiotherapy-Induced Severe Oral Mucositis
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
U.S. STOCKS ON THE MOVE-Virios, McAfee, Perrigo
Galera Therapeutics up as pancreatic cancer therapy improves overall survival
Brief: Galera Announces Final Results From Pancreatic Cancer Trial Showing Improvements On All Efficacy Parameters
Brief: Galera Says Entered Manufacturing Services Agreement With Patheon Manufacturing Services
Galera Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Galera Therapeutics Inc Posts Q2 Loss Per Share $0.88
Galera Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Galera Announces First Patient Dosed With GC4711 In Phase 2B Greco-2 Trial In Patients With Pancreatic Cancer